Italian biotech company Aptadir, which develops RNA inhibitor therapies for genetic diseases, has closed a €40 million seed round with investors including 4BIO Ventures and CDP Venture Capital.
Aptadir Therapeutics, a biotech company developing a new class of RNA inhibitor-based therapies for the treatment of intractable genetic disorders, has announced that it has closed a seed funding round worth 40 million euros.
